Search Results for "Alnylam"
Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.
More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.
For more information about our FDA-approved therapies, please see the Full Prescribing Information:
Screening, Recognition, and Barriers to Diagnosis of ATTR
This deck highlights the screening, recognition, and barriers of diagnosis in ATTR.
This deck highlights the screening, recognition, and barriers of diagnosis in ATTR.
Insights from the HELIOS-A Study
This deck highlights data from the Phase 3 HELIOS-A trial of vutrisiran in patients with hATTR-PN.
This deck highlights data from the Phase 3 HELIOS-A trial of vutrisiran in patients with hATTR-PN.
Renin-Angiotensin System (RAS) In Hypertension Video
This video highlights how the up-regulation of RAS contributes to hypertension. This resource is intended to support scientific exchange. The information provided is not intended to serve as recommendations for clinical practice.
This video highlights how the up-regulation of RAS contributes to hypertension. This resource is intended to support scientific exchange. The information provided is not intended to serve as recommendations for clinical practice.
ATTR Disease Management
This deck highlights management and monitoring of patients with ATTR.
This deck highlights management and monitoring of patients with ATTR.
ATTRv-PN Expert Opinion Slide Deck
Recommendations from a panel of experts for the diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States.
Recommendations from a panel of experts for the diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States.
